October 3, 2023 11:24 AM EDTUpdated 03:49 PM
News Briefing

Re­gen­eron ex­pands CRISPR deal with In­tel­lia; Cap­si­da, Kate's gene ther­a­py man­u­fac­tur­ing deal; Bio­haven’s $225M of­fer­ing

Ayisha Sharma

News Reporter

Jaimy Lee

Deputy Editor

Plus, Coda­genix to ad­vance Covid-19 nasal vac­cine with BAR­DA sup­port.

Re­gen­eron, In­tel­lia ex­tend CRISPR deal: Re­gen­eron Phar­ma­ceu­ti­cals and In­tel­lia Ther­a­peu­tics are

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times